Table 2.
All treatments, deaths, and ocular preservations in survivors
| Disease | Patients | Treatments | Number of Patients | Death | Binocular Survivors (%) | |
|---|---|---|---|---|---|---|
| Trilateral-onset n = 1 | n = 1 | RT and Systemic chemotherapy | 1 | 1 (Pt 2) | 0 | (0%) |
| Bilateral-onset n = 38 | n = 38 | Enucleation and/or Local therapy alone | 5 | 0 | 1 / 5 | (25%) |
| Enucleation and/or Local therapy with RT | 8 | 2 (Pt 3, Pt 6) | 2 / 6 | (33%) | ||
| Systemic chemotherapy | 25 | 2 (Pt 5, Pt 1) | 0 / 8a | (0%) | ||
| with RT (and IAC) | 10 (1) | 2 | 2/ 15 | (13%) | ||
| w/o RT (and IAC) | 15 (5) | 0 | 0 | (0%) | ||
| 4/38 (10.5%) | 5/38 | (13.2%) | ||||
| Unilateral-onset n = 77 | n = 77 | Enucleation and/or Local therapy alone | 52 | 0 | 0 / 52 | (0%) |
| Enucleation and/or Local therapy with RT | 2 | 0 | 0 / 2 | (0%) | ||
| Systemic chemotherapy | 23 | 1 (Pt 4) | 0 / 4 | (0%) | ||
| with RT | 5 | 1 | 4 / 18 | (22%) | ||
| w/o RT (and IAC) | 18 (4) | 0 | 0 / 52 | (0%) | ||
| 1/77 (1.3%) | 4/77 | (5.2%) | ||||
aTwo survivors were blind due to binocular loss